Capricor Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a price target of $35.
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics shares rose after Piper Sandler initiated coverage with an Overweight rating and set a price target of $35.
October 21, 2024 | 7:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics shares increased following Piper Sandler's initiation of coverage with an Overweight rating and a $35 price target.
The initiation of coverage by Piper Sandler with an Overweight rating and a $35 price target is a positive signal for investors, likely boosting short-term stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100